CN116549433A - Application of luteolin in preparation of platelet glycoprotein VI inhibitor - Google Patents
Application of luteolin in preparation of platelet glycoprotein VI inhibitor Download PDFInfo
- Publication number
- CN116549433A CN116549433A CN202310385361.1A CN202310385361A CN116549433A CN 116549433 A CN116549433 A CN 116549433A CN 202310385361 A CN202310385361 A CN 202310385361A CN 116549433 A CN116549433 A CN 116549433A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- gpvi
- platelet
- inhibitor
- platelet aggregation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 title claims abstract description 72
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 71
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 235000009498 luteolin Nutrition 0.000 title claims abstract description 71
- 102100038394 Platelet glycoprotein VI Human genes 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108010064773 platelet membrane glycoprotein VI Proteins 0.000 title claims abstract description 12
- 229940118144 Glycoprotein VI inhibitor Drugs 0.000 title claims abstract description 10
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 33
- 239000003112 inhibitor Substances 0.000 claims abstract description 15
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 14
- 230000000702 anti-platelet effect Effects 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 12
- 239000012190 activator Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000005764 inhibitory process Effects 0.000 claims abstract description 8
- 101710194982 Platelet glycoprotein VI Proteins 0.000 claims abstract 7
- 231100000673 dose–response relationship Toxicity 0.000 claims description 5
- 229940127218 antiplatelet drug Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000003993 interaction Effects 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 abstract description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 238000013176 antiplatelet therapy Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 238000004879 turbidimetry Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 description 13
- 238000004220 aggregation Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 108010089485 convulxin Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000007347 Apyrase Human genes 0.000 description 2
- 108010007730 Apyrase Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001013934 Erigeron breviscapus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000006502 antiplatelets effects Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- -1 luteolin compound Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010048623 Collagen Receptors Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000001 effect on platelet aggregation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of luteolin in preparation of a platelet glycoprotein VI inhibitor, and belongs to the technical field of medical biology. The luteolin anti-platelet is an anti-GPVI specific activator induced platelet aggregation reaction, and the result of optical turbidimetry detection shows that the luteolin has a remarkable inhibition effect on the GPVI specific activator induced human platelet aggregation. The interaction of luteolin and GPVI shows that the luteolin directly interacts with GPVI through a surface plasmon resonance detection result. Luteolin can be used for not only the development of GPVI inhibitors and medicines, but also monitoring the existing antiplatelet therapy.
Description
Technical Field
The invention belongs to the technical field of medical biology, and particularly relates to application of luteolin in preparation of a platelet glycoprotein VI inhibitor.
Technical Field
Platelets play an important role in arterial thrombosis, and classical antiplatelet aspirin and novel drug which blocks alpha IIb beta 3 from combining with fibrinogen, such as Acximab, play an important clinical treatment role, but potential risks such as gastrointestinal reaction and hemorrhage exist. The development of antiplatelet medicines with better safety and effectiveness has important clinical and social values.
Vascular endothelial cells are damaged or plaque ruptured and subendothelial collagen exposure initiates acute thrombosis. Collagen, together with platelet surface glycoprotein VI (GPVI) and integrin- α2β1, activates the integrin αiibβ3 activation pathway, causing platelet activation and aggregation. The activated substances such as thrombin released in the platelet activation process further promote platelet aggregation, and finally lead to thrombus formation. The currently reported small molecule inhibitors of GPVI are few and none are in clinical use.
Luteolin is a major component of flavonoids in erigeron breviscapus, and is also widely found in vegetables, fruits and herbs. Many researches show that luteolin has anti-inflammatory and anti-oxidative stress activities and plays a positive role in treating cardiovascular diseases such as coronary heart disease, diabetes and the like. Although the prior art reports the antiplatelet and antithrombotic functions of luteolin, the activity of luteolin in a platelet glycoprotein VI inhibitor is not reported.
The invention comprises the following steps:
the invention aims to provide application of luteolin in preparation of platelet glycoprotein VI inhibitor. The luteolin related by the invention is a main component of flavonoids in erigeron breviscapus, and also widely exists in vegetables, fruits and Chinese herbal medicines. Experiments show that luteolin selectively resists platelet aggregation induced by GPVI specific inhibitors. Thus, luteolin can be used in antiplatelet drugs. Luteolin may also be used in the preparation of GPVI specific inhibitors in combination with a composition of one or more pharmaceutically acceptable carriers.
In order to achieve the above object of the present invention, the present invention provides the following technical solutions:
application of luteolin in preparing platelet glycoprotein VI inhibitor is provided.
According to the application of luteolin in preparing platelet glycoprotein VI inhibitor, wherein the luteolin interacts with GPVI to form K D =4.13μM。
The application of luteolin in preparing antiplatelet medicines, wherein the antiplatelet effect of luteolin is to achieve the antiplatelet aggregation effect by the antiplatelet aggregation effect induced by the GPVI specific inhibitor.
The application of luteolin in preparing antiplatelet medicines, wherein the antiplatelet effect of the luteolin is platelet aggregation induced by an antiplatelet GPVI specific inhibitor, and the inhibition efficiency is dose-dependent, so that the antiplatelet aggregation effect is achieved.
Application of luteolin in preparing anti-platelet medicine for inhibiting platelet aggregation induced by GPVI specific activator is provided.
According to the application of the luteolin in preparing a platelet glycoprotein VI inhibitor, the luteolin has the effects of resisting platelet aggregation induced by a GPVI specific inhibitor, and the inhibition efficiency is dose-dependent.
When the luteolin is used as a medicament, the luteolin can be directly used or used in the form of a pharmaceutical composition. The pharmaceutical composition contains 0.1-99% of luteolin compound, preferably 0.5-90% of luteolin as effective component, and pharmaceutically acceptable adjuvants or carriers for human and animals. The various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional production methods in the pharmaceutical field. For example by mixing the active ingredient with one or more carriers and then forming it into the desired dosage form.
The pharmaceutically acceptable carrier refers to a conventional pharmaceutical carrier in the pharmaceutical field, for example: diluents, excipients such as water, etc., fillers such as starch, sucrose, etc.; binders such as cellulose derivatives, alginates, gelatin and polyvinylpyrrolidone; humectants such as glycerol; disintegrants such as agar, calcium carbonate and sodium bicarbonate; absorption promoters such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and soap clay; lubricants such as talc, calcium stearate and magnesium stearate, polyethylene glycol, and the like. Other adjuvants such as flavoring agent, sweetener, etc. can also be added into the composition.
Compared with the prior art, the invention has the advantages that:
1. the invention discovers a new medical application for luteolin, the clinical existing medicine does not have an inhibitor of small molecular platelet membrane glycoprotein VI, the luteolin can be used as the inhibitor of the target point, and a new application field is developed.
2. The luteolin product of the invention has rich source, low cost, no toxic or side effect, simple preparation process, convenient use, and can be prepared into oral dosage forms, injection dosage forms, tablets and the like.
3. The luteolin product can obviously inhibit platelet aggregation induced by GPVI specific inhibitor, and the inhibition efficiency is dose-dependent. Can effectively inhibit platelet aggregation and can be effectively used as an antiplatelet drug.
Drawings
FIG. 1 is a graph and bar graph of the effect of luteolin on activator-induced platelet aggregation;
FIG. 2 is a graph showing the interaction of luteolin with GPVI by surface plasmon resonance analysis.
Detailed Description
The following examples are provided to illustrate the present invention in more detail with reference to the accompanying drawings. But are not intended to limit the invention.
Example 1
Luteolin selectively inhibits GPVI-specific inhibitor Convulxin-induced human platelet aggregation in vitro.
(1) Healthy volunteers of experimental human platelet origin sign informed consent for blood donation and are given nutritional supplements. Venous whole blood was collected, and the apheresis platelet was isolated from Kunming blood centers and collected in the department of Hematology, university of Kunming medical science.
(2) The specific implementation mode is as follows:
step one, dissolving luteolin by using DMSO.
Step two, washing the platelets. Taking 1mL of human single blood collection platelets stored by constant-temperature shaking at 25 ℃ in a 1.5mL centrifuge tube, adding EDTA with a final concentration of 5mM and Apyrase (prepared by normal saline to prevent platelet aggregation in the centrifugation process) with a final concentration of 0.1U/mL, and centrifuging at 400g at room temperature for 10 minutes; the supernatant was discarded from the centrifuged human apheresis platelets, and 1mL Tyrode's Buffer B was added to the cell pellet (137mM NaCl,27mM KCl,1mM MgCl 2 ,0.42mM NaH 2 PO 4 5.5mM Glucose,5.55mM HEPES,0.25% Bovine Serum Albumin, pH 6.5), 5mM EDTA,0.1U/mL Apyrase were gently blown up, and centrifuged again at 400g for 10min at room temperature; with Tyrode's Buffer A (137mMNaCl,27mM KCl,1mM MgCl) 2 ,0.42mM NaH 2 PO 4 5.5mM Glucose,5.55mM HEPES,0.25% Bovine Serum Albumin, pH 7.4) the centrifuged platelets were resuspended and the platelet count was adjusted to 150-250X 10 9 and/L. 70rpm,25 ℃ vibration storage, washing platelets in 1 hours.
Step three, 400. Mu.L of the washed platelet resuspension was aspirated and preheated at 37℃for 5min. Luteolin was added to the experimental group at a final concentration of 2.5-25. Mu.M, and an equal volume of DMSO was added to the positive control group (Vehicle) and incubated at 37℃for 10min. Opening a platelet aggregation instrument, setting parameters according to requirements, putting a magnetic rod into the incubated washed platelets, inserting a platelet reaction cup with the magnetic stirring rod into a detection hole of a machine, placing the platelet reaction cup in a test area of the platelet aggregation instrument, zeroing, adding collagen, and observing the influence of luteolin on platelet aggregation caused by different activators at 37 ℃ and 1200rpm for 10min. And drawing a corresponding scatter diagram according to a platelet aggregation curve recorded by the platelet aggregation instrument. Experimental data were statistically analyzed using GraphPadPrism 9.0 software. The comparison was performed using analysis of variance. p <0.05 then the difference is considered statistically significant.
As shown in fig. 1 a of the specification: human washed platelets were incubated with luteolin or DMSO at various concentrations for 10min at 37 ℃, activated with the GPVI specific activator Convulxin (5 ng/mL), and platelet aggregation curves were plotted and recorded using a platelet aggregation instrument. The abscissa is the time depicted by the aggregation curve, and the ordinate is the real-time aggregation rate of platelets depicted by the platelet aggregation meter. Presented in fig. 1 a is a platelet aggregation rate curve representative of the aggregation experiment. At the beginning of the aggregation test, the platelet aggregation rate was 0%, convulxin was added immediately, and the platelets of the positive control (Vehicle) test group began to aggregate when the test was carried out for about 10 seconds. When the aggregation test was carried out until about 2 minutes, the aggregation rate of the Vehicle group reached about 80% peak, the aggregation rate of the 2.5. Mu.M luteolin group reached about 70% peak, and the aggregation rate of the 100. Mu.M luteolin group reached about 0%. Description the diagram B in fig. 1 shows: comparison of platelet aggregation peaks for Vehicle and luteolin (2.5-100. Mu.M) groups at different concentrations. C-F in FIG. 1 of the specification: effects of 25 μm luteolin on platelet aggregation induced by different activators (ADP, thrombin and U46619) aggregation graphs and bars. The experiments of Vehicle and luteolin with different concentrations are repeated four times, the peak value of platelet aggregation is expressed by mean ± standard error, wherein the difference is statistically significant, and p is less than or equal to 0.0001 compared with the Vehicle group. As can be seen from fig. 1: luteolin can obviously inhibit platelet aggregation induced by GPVI specific activator Convulxin, and its inhibition efficiency is dose dependent, IC 50 =8.66 μΜ. Although luteolin also has a certain inhibition effect on platelet aggregation induced by U46619, the inhibition effect of luteolin on platelet aggregation induced by different activators is selective only at a high concentration of 100 mu M, and luteolin mainly inhibits platelet aggregation mediated by GPVI receptors.
Example 2
Surface plasmon resonance plot of luteolin interaction with GPVI.
This experiment was used to verify the direct interaction of luteolin with GPVI in vitro and calculate the equilibrium constants of both.
The specific implementation mode is as follows:
GPVI protein (human recombinant GPVI is from MCE company, product number HY-P77952) is immobilized on a chip, luteolin with different concentrations is sequentially added to analyze affinity with GPVI, reaction signals within 90 seconds are recorded, a kinetic curve is made, and relevant parameters are calculated.
As can be seen from fig. 2, the affinity of GPVI to luteolin (K D ) 4.13. Mu.M. In recent years, a variety of small molecules have been reported in the literature to inhibit GPVI mediated platelet aggregation, but there is evidence that small molecules that interact directly with GPVI are fewer and have generally not high affinity, for example: honokiol, K D =289μM(Lee TY, Chang CC, Lu WJ, et al., Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets: Functional ex vivo and in vivo studies. Sci Rep, 2017;7:40002.),Losartan K D =170μM(Ono K, Ueda H, Yoshizawa Y, et al., Structural basis for platelet antiaggregationby angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem, 2010;53(5):2087-93.),GSK669 K D =14.4 μm (Pan G, chang L, zhang J, et al, GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet gpvi, biochem Pharmacol,2021; 183:114315), and the like. From this, the affinity of luteolin to GPVI (K D ) 4.13. Mu.M, is the higher affinity of the small molecules reported to date. The luteolin is used as a template for molecular transformation, and a small molecular inhibitor with higher affinity is synthesized to prepare a novel high-efficiency anti-GPVI small molecular preparation.
Example 3:
tablet: luteolin 10mg, lactose 180 mg, starch 55 mg, magnesium stearate 5 mg.
The preparation method comprises the following steps: mixing luteolin, lactose and starch, wetting with water, sieving the wetted mixture, drying, sieving again, adding magnesium stearate, tabletting the mixture, each tablet having weight of 250 mg and compound content of 10 mg.
Example 4:
ampoule agent: luteolin, or a pharmaceutically acceptable salt thereof 2 mg, sodium chloride 10 mg.
The preparation method comprises the following steps: dissolving luteolin and sodium chloride in appropriate amount of injectable water, filtering to obtain solution, and packaging into ampoule under aseptic condition.
Example 5:
freeze-dried preparation for injection: luteolin 10mg, sodium bicarbonate 2 mg, mannitol 252 mg.
The preparation method comprises the following steps: dissolving sodium bicarbonate and mannitol in water for injection, adding activated carbon for adsorption for 30 min to remove pyrogen, filtering to remove activated carbon, adding luteolin into the filtrate, performing ultrasonic treatment to dissolve, adjusting pH to 5.0-7.0 with 1N hydrochloric acid, filtering with microporous membrane, adding water for injection, packaging, freeze drying, plugging, and capping.
Example 6:
the capsule comprises the following components: luteolin 10mg, lactose 187 mg, magnesium stearate 3mg.
The preparation method comprises the following steps: mixing luteolin with cosolvent, sieving, mixing, and encapsulating into hard gelatin capsules with weight of 200 mg and active ingredient content of 10 mg.
The scope of the present invention is not limited to the above-described embodiments, which are provided only for the purpose of aiding in explaining and explaining the present invention, but not limiting the scope of the present invention, as long as the design is identical to the design of the present invention or is equivalent thereto, and falls within the scope of the present invention as claimed.
Claims (5)
1. Application of luteolin in preparing platelet glycoprotein VI inhibitor is provided.
2. Use of luteolin according to claim 1 for the preparation of an inhibitor of platelet glycoprotein VI, characterized in that wherein said luteolin interacts with GPVI at K D =4.13μM。
3. Use of luteolin in the manufacture of an antiplatelet agent for use in the treatment of GPVI-specific inhibitor-induced platelet aggregation.
4. The luteolin is applied to the preparation of platelet aggregation induced by the anti-GPVI specific inhibitor, and the inhibition efficiency of the luteolin is dose-dependent, so that the anti-platelet aggregation effect is achieved.
5. Application of luteolin in preparing anti-platelet medicine for inhibiting platelet aggregation induced by GPVI specific activator is provided.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310385361.1A CN116549433A (en) | 2023-04-12 | 2023-04-12 | Application of luteolin in preparation of platelet glycoprotein VI inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310385361.1A CN116549433A (en) | 2023-04-12 | 2023-04-12 | Application of luteolin in preparation of platelet glycoprotein VI inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116549433A true CN116549433A (en) | 2023-08-08 |
Family
ID=87502813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310385361.1A Pending CN116549433A (en) | 2023-04-12 | 2023-04-12 | Application of luteolin in preparation of platelet glycoprotein VI inhibitor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116549433A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101352416A (en) * | 2006-10-10 | 2009-01-28 | 上海格鲁奥丽生物医药技术有限公司 | Luteolin solution composition |
-
2023
- 2023-04-12 CN CN202310385361.1A patent/CN116549433A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101352416A (en) * | 2006-10-10 | 2009-01-28 | 上海格鲁奥丽生物医药技术有限公司 | Luteolin solution composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2230624T5 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMPOUND THAT HAS ANTI-XA ACTIVITY AND AN ANTAGONIST COMPOUND OF THE PLAQUETARY AGGREGATION. | |
CN106075455A (en) | The method identifying the critical patient of the risk raising developing into organ failure and the compound treated for it | |
KR20160033792A (en) | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | |
Wu et al. | Differential effects of two doses of aspirin on platelets-vessel wall introduction in vivo. | |
ES2298342T3 (en) | BETAINE GLYCINE AND ITS USE AS AN ANTI-HEMORRAGIC AGENT. | |
KR20090040759A (en) | Composition for anticoagulation comprising cattail pollen extracts | |
CN116549433A (en) | Application of luteolin in preparation of platelet glycoprotein VI inhibitor | |
JPH0114206B2 (en) | ||
JP5718340B2 (en) | Thrombus formation inhibitor | |
JPH06234636A (en) | Use of leflunomide for inhibiting interleukin-8 | |
CN113116885A (en) | Application of tea polyphenol compounds in preparation of antithrombotic drugs | |
CN113244225B (en) | Application of pseudolaric acid B in preparation of antiplatelet drugs | |
Mannucci et al. | Platelet functions after intravenous administration in man of cyclic-AMP and related drugs | |
US20100168406A1 (en) | USE OF GINSENOSIDE Rb2 MONOMER IN THE MANUFACTURE OF MEDICAMENTS FOR THROMBOLYSIS | |
JP6389009B2 (en) | Drug composition containing ginkgolide B and factor Xa inhibitor, method for producing the same, and use thereof | |
CN104173334B (en) | A kind of pharmaceutical composition of antiplatelet aggregation | |
KR20180129081A (en) | A Composition comprising the gintonin for preventing or treating thrombosis | |
CN102151282B (en) | Application of iridoid glycoside and derivatives thereof as plasmin inhibitor and medicine composites of plasmin inhibitor | |
CN115990178B (en) | Application of compound in preparation of anticoagulant drugs | |
CN106420736A (en) | Application of berberine in preparation of drug for treating fibrinolysis system disorder related diseases | |
CN109939110A (en) | Jateorrhizine is preparing the application in antithrombotic reagent | |
JPS629567B2 (en) | ||
CN105456256A (en) | Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition | |
JP2001520200A (en) | Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator | |
CN101138635B (en) | Fibrin glue vasodilation agent sustained-release long-acting composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |